Review of toxicity for endpoints identified by the COT

In this guide

In this guide

- 1. Executive Summary Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 2. <u>Introduction Statement on the safety of Titanium Dioxide (E171) as a Food</u>
 Additive
- 3. <u>Titanium Dioxide Statement on the safety of Titanium Dioxide (E171) as a</u> Food Additive
- 4. Absorption, Distribution, Metabolism and Excretion (ADME)
- 5. Review of toxicity for endpoints identified by the COT
- 6. Reproductive and Developmental Toxicity Statement on the safety of Titanium Dioxide (E171) as a Food Additive_
- 7. Aberrant Crypt Foci (ACF) as a potential biomarker for carcinogenicity
- 8. <u>Genotoxicity Statement on the safety of Titanium Dioxide (E171) as a Food</u>
 Additive
- 9. <u>Inflammation and Immunotoxicity Statement on the safety of Titanium Dioxide (E171) as a Food Additive</u>
- 10. Neurotoxicity Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 11. <u>Establishment of a Health-Based Guidance Value (HBGV) Statement on the</u> safety of Titanium Dioxide (E171) as a Food Additive
- 12. Exposure Assessment Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 13. <u>Assumptions and uncertainties Statement on the safety of Titanium Dioxide</u> (E171) as a Food Additive
- 14. Risk characterisation Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 15. <u>Conclusions Statement on the safety of Titanium Dioxide (E171) as a Food</u>
 Additive

- 16. Abbreviations Table Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 17. References Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 18. Annex A Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 19. Annex B Summary table of studies
- 20. Annex C Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 21. Annex D Statement on the safety of Titanium Dioxide (E171) as a Food Additive
- 119. The following endpoints were reviewed, initially by the COT and then in more detail by a sub-group of COT Members: aberrant crypt foci (as a potential marker for carcinogenicity), genotoxicity (also reviewed by COM), inflammation and immunotoxicity, allergenicity, reproductive and developmental toxicity and neurotoxicity. The COT's reviews are discussed in detail in each of these sections for the endpoints.